405 related articles for article (PubMed ID: 20529556)
1. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
4. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
Imel EA; Hui SL; Econs MJ
J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
[TBL] [Abstract][Full Text] [Related]
5. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.
Yamazaki Y; Okazaki R; Shibata M; Hasegawa Y; Satoh K; Tajima T; Takeuchi Y; Fujita T; Nakahara K; Yamashita T; Fukumoto S
J Clin Endocrinol Metab; 2002 Nov; 87(11):4957-60. PubMed ID: 12414858
[TBL] [Abstract][Full Text] [Related]
6. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna.
Ward LM; Rauch F; White KE; Filler G; Matzinger MA; Letts M; Travers R; Econs MJ; Glorieux FH
Bone; 2004 May; 34(5):905-11. PubMed ID: 15121023
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
Bielesz B
Eur J Clin Invest; 2006 Aug; 36 Suppl 2():34-42. PubMed ID: 16884396
[TBL] [Abstract][Full Text] [Related]
8. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
9. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome.
Yamamoto T; Imanishi Y; Kinoshita E; Nakagomi Y; Shimizu N; Miyauchi A; Satomura K; Koshiyama H; Inaba M; Nishizawa Y; Jüppner H; Ozono K
J Bone Miner Metab; 2005; 23(3):231-7. PubMed ID: 15838626
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.
Aono Y; Yamazaki Y; Yasutake J; Kawata T; Hasegawa H; Urakawa I; Fujita T; Wada M; Yamashita T; Fukumoto S; Shimada T
J Bone Miner Res; 2009 Nov; 24(11):1879-88. PubMed ID: 19419316
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 23 and its receptors.
Yu X; White KE
Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
[TBL] [Abstract][Full Text] [Related]
12. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.
Harrell RM; Lyles KW; Harrelson JM; Friedman NE; Drezner MK
J Clin Invest; 1985 Jun; 75(6):1858-68. PubMed ID: 3839245
[TBL] [Abstract][Full Text] [Related]
13. Regulation of phosphate homeostasis in infants, children, and adolescents, and the role of phosphatonins in this process.
Garabedian M
Curr Opin Pediatr; 2007 Aug; 19(4):488-91. PubMed ID: 17630616
[TBL] [Abstract][Full Text] [Related]
14. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
Drezner MK; Lyles KW; Haussler MR; Harrelson JM
J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
[TBL] [Abstract][Full Text] [Related]
16. [Hypophosphatemic rickets/osteomalacia. - Mainly on patients with PHEX mutations -].
Hasegawa Y; Miyamoto J
Clin Calcium; 2007 Oct; 17(10):1592-9. PubMed ID: 17906414
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of bone markers in hypophosphatemic rickets/osteomalacia.
Nagata Y; Imanishi Y; Ishii A; Kurajoh M; Motoyama K; Morioka T; Naka H; Mori K; Miki T; Emoto M; Inaba M
Endocrine; 2011 Oct; 40(2):315-7. PubMed ID: 21822687
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
19. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
Michigami T
Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.
Collins MT; Lindsay JR; Jain A; Kelly MH; Cutler CM; Weinstein LS; Liu J; Fedarko NS; Winer KK
J Bone Miner Res; 2005 Nov; 20(11):1944-50. PubMed ID: 16234967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
